Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

NCT ID: NCT06061445

Last Updated: 2024-04-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-09
• Study Completion Date: 2025-12-31

Brief Summary

The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).

Conditions

Stage IIIA Hepatocellular Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

treatment group

Radiotherapy Combined with TKI and Anti-PD-1 Antibody

Group Type: EXPERIMENTAL

Radiotherapy combined with TKI and Anti-PD-1 Antibody

Intervention Type: COMBINATION_PRODUCT

After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.

Interventions

Radiotherapy combined with TKI and Anti-PD-1 Antibody

After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

• Patients with primary hepatocellular carcinoma who strictly meet the clinical diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" (2022 edition) or who have been confirmed by histopathology or human cytology, There was at least one measurable lesion (spiral CT scan length ≥10mm or malignant lymph node short diameter ≥15mm according to RECIST1.1 standard);
• Patients with advanced primary hepatocellular carcinoma who have not received systematic treatment and cannot be surgically resectable;
• CNLC was divided into stage IIIA, VP1-3 type;
• Child-Pugh classification of liver function is grade A (5-6 points);
• ECOG PS score 0-1;
• Expected survival ≥12 weeks;
• Patients with active hepatitis B virus (HBV) infection must be willing to receive antiviral treatment throughout the study period; Hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral therapy according to standard local treatment guidelines and have liver function within CTCAE level 1 elevation;
• The major organs function normally and meet the following criteria :

1. The blood routine examination criteria should meet :(no blood transfusion within 14 days)

1. Hemoglobin (HB)≥90g/L,

2. White blood cell count (WBC)≥3×109/L,

3. Absolute neutrophil count (ANC)≥1.5×109/L,

4. platelets (PLT)≥75×109/L;

2. Biochemical examination should meet the following criteria:

<!-- -->

1. Bilirubin (BIL)< 1.5 times the upper limit of normal value (ULN);

2. Alanine aminotransferase (ALT) and aspartate aminotransferase AST<5ULN;

3. Serum creatinine (Cr)≤1.5ULN

• Women of childbearing age must have a negative pregnancy test (serum) or urine HCG test within 7 days prior to admission and be willing to use an appropriate method of contraception during the trial and 8 weeks after the last dose of the test drug; For males, they should be surgically sterilized or agree to use appropriate methods to avoid pregnancy during the trial and for 8 weeks after the last dose of the trial drug;
• The subjects voluntarily joined the study, had good compliance, and cooperated with follow-up.

Exclusion Criteria

• Pregnant or lactating women;
• Patients with autoimmune diseases, organ/hematopoietic stem cell transplantation, or other malignancies (except cured cutaneous basal cell carcinoma and cervical carcinoma in situ);
• Patients with consciousness disorder or inability to cooperate with treatment, combined with mental illness;
• Patients with a history of epigastric radiotherapy;
• Patients who fail to follow dose limits for vital organs in the radiotherapy program, including patients with normal liver tissue less than 700 ml in the radiotherapy program;
• Patients who have participated in other clinical trials in the past three months;
• Previously received targeted therapy or other PD-1/PD-L1 inhibitor therapy;
• Received major surgery or chemotherapy, radiation therapy or other focal systemic therapy within 1 month before enrollment;
• Immunosuppressive agents or systemic hormone therapy (dose >10mg/ day prednisone or other therapeutic hormones) were used within 14 days before enrollment to achieve immunosuppression;
• Liver function was classified as Child-Pugh C, which could not be improved by liver protection treatment.
• Esophageal (fundus) varices rupture and bleeding within 1 month before treatment.
• Uncorrectable coagulation dysfunction and severe blood abnormalities, with a tendency to severe bleeding. Platelet count <50×109/L and severe coagulation dysfunction can not withstand surgery (anticoagulant therapy and/or anticoagulant drug use should be stopped more than 1 week before radiotherapy);
• Refractory ascites, bad fluid;
• Active infection, especially inflammation of the biliary system;
• Severe liver, kidney, heart, lung, brain and other major organ failure;
• People who have been allergic to any component of PD-1 monoclonal antibody or other similar experimental drugs;
• Have high blood pressure and can not be reduced to normal by antihypertensive medication

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fujian Cancer Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fujian Cancer Hospital

Fuzhou, Fujian, China

Site Status: RECRUITING

Countries

China

Central Contacts

Shaohua Xu, Master

Role: CONTACT

xshzss@126.com

13599253863

Facility Contacts

Shaohua Xu, Master

Role: primary

xshzss@126.com

13599253863

Other Identifiers

RTI

Identifier Type: -

Identifier Source: org_study_id